Mosaic ImmunoEngineering Research and Development Expenses 2010-2025 | CPMV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mosaic ImmunoEngineering research and development expenses from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Mosaic ImmunoEngineering Research and Development Expenses 2010-2025 | CPMV

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Mosaic ImmunoEngineering research and development expenses from 2010 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$247.9B
Amgen (AMGN)	$155B
Gilead Sciences (GILD)	$141.4B
Vertex Pharmaceuticals (VRTX)	$99.8B
Bristol Myers Squibb (BMY)	$96.9B
GSK (GSK)	$81.3B
CSL (CSLLY)	$67.8B
Regeneron Pharmaceuticals (REGN)	$62.2B
Alnylam Pharmaceuticals (ALNY)	$59.5B
Argenex SE (ARGX)	$43.3B
Insmed (INSM)	$28.4B
BioNTech SE (BNTX)	$24.8B
Royalty Pharma (RPRX)	$21B
Biogen (BIIB)	$20B
Incyte (INCY)	$16.6B
Genmab (GNMSF)	$16B
Genmab (GMAB)	$15.9B
Illumina (ILMN)	$15.3B
Ascendis Pharma (ASND)	$11.8B
BioMarin Pharmaceutical (BMRN)	$11.3B
Swedish Orphan Biovitrum (BIOVF)	$10.9B
QIAGEN (QGEN)	$10.7B
Exelixis (EXEL)	$10.4B
Moderna (MRNA)	$9.8B
Verona Pharma American Depositary Share (VRNA)	$9.1B
Exact Sciences (EXAS)	$8.8B
Bio-Techne Corp (TECH)	$8.8B
Halozyme Therapeutics (HALO)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$8.2B